Searched for
SUBOXONE
Dr Reddy’s Q3 Results Preview: Profit may drop on lower Revlimid sales, higher costsThe drugmaker is expected to report a 1.1% YoY drop in consolidated net profit to Rs 1,247 crore, according to the average of estimates giv...- Dr Reddy's gearing up to get substantial slice of Revlimid generic opportunity in USRevlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...
- Dr Reddy’s Labs down ahead of Q1 results, here’s what to expectKotak Institutional Equities believes that the pharma company may report 49.70 per cent year-on-year rise in reported profit after tax for ...
- DRL plunges 5% post Q4 numbers; brokerages mixedDRL reported a 44 per cent year-on-year rise in profit at Rs 434.40 crore on Monday.
- Dr Reddy's re-launches generic version of Suboxone in US marketIndivior is in a legal battle against the launch of the copycat version of its opioid addiction treatment by competitors.
- DRL stock slips 5% after US court orderThe scrip was 5.30 per cent down at Rs 2,565.60 at around 02.12 pm.
- Buy Dr. Reddy's Laboratories, target Rs 3,350: Edelweiss Financial ServicesBuy Dr. Reddy's Laboratories Ltd. at a price target of Rs 3350.0 .
- ‘Nod to sell Opioid drug in US positive for Dr Reddy’s stock’The company can resume at-risk launch of Suboxone with favourable ruling from the appeals court.
- Share market update: Pharma shares bullish; Dr. Reddy's Lab surges nearly 7%Benchmark NSE Nifty50 index was down 90.45 points at 10,565.75 while BSE Sensex was down 354.82 points at 35,119.69 around 11:30 am.
- Dr Reddy's climbs 8% on nod for generic SuboxoneIn June, the USFDA had approved Dr Reddy's Buprenorphine and Naloxone Sublingual Film.
- Suboxone verdict will be the most important trigger for US market: Saumen Chakraborty, Dr Reddy’sSituation improving in parts of EM including Brazil and other LatAm countries, says the DRL president.
- DRL posts 77% jump in Q2 profit at Rs 504 crore, beats Street estimatesThe company had reported Rs 284.90 croe profit in the yer-ago quarter.
- Dr Reddy’s Laboratories gains 3% on receiving EIR for Srikakulam plantThe pharma major last month reported nearly eight-fold jump in consolidated profit after tax to Rs 456.1 crore for the first quarter of 201...
- Dr Reddy's Q1 profit jumps 8 times YoY to Rs 456 crore, beats Street estimatesAnalysts in an ETNow poll had predicted a profit of Rs 295 crore for the quarter under review.
- DRL takes a hit of 10% on US court orderIndivior sees a $25 million dent on its revenues due to the product of Dr Reddy's.
- US court prevents Dr Reddy's Laboratories from selling opioid dependence treatment drugThe court has also ordered the parties to submit a final proposed injunction order on Monday.
- Neutral on Dr Reddy's Lab, target Rs 2275: Motilal Oswal SecuritiesNeutral on Dr. Reddy's Laboratories Ltd. at a price target of Rs 2275.0 .
- Dr Reddy's gets temporary restraining order on sale of generic Suboxone film in USDr Reddy's said in a BSE filing that the company remains confident in its legal positions on this patent.
- Dr Reddy's Laboratories gets USFDA nod for generic version of SuboxoneThe company, which is launching the product in the US, said approval has been granted in the strengths of 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg...
- ETMarkets After Hours: Dr Reddy's gets a healthy boost; Sun TV jumps 10%The Nifty50 index of NSE closed at 9,974 with 40 constituents closing in the green and rest in the red.
Load More
